Zhang, Min Lang, Xianghua Chen, Xinyi Lv, Yuke
Published in
Molecular biotechnology
The advantage of an increasing amount of bioinformatics data on leukemias intrigued us to explore the hot-spot mutation profiles and investigate the implications of those hot-spot mutations in patient survival. We retrieved somatic mutations and their distribution in protein domains through data analysis of The Cancer Genome Atlas and cBioPortal da...
Daver, Naval Vyas, Paresh Kambhampati, Suman Al Malki, Monzr Larson, Richard Asch, Adam Mannis, Gabriel Chai-Ho, Wanxing Tanaka, Tiffany Bradley, Terrence
...
PURPOSE: Magrolimab is a first-in-class humanized monoclonal antibody against cluster of differentiation 47, an antiphagocytic signal used by cancer cells to evade phagocytosis. Azacitidine upregulates prophagocytic signals on AML cells, further increasing phagocytosis when combined with magrolimab. We report final phase Ib data for magrolimab with...
Rundberg Nilsson, Alexandra Shalapour, Shabnam Cammenga, Jörg Karin, Michael Xian, Hongxu
Hematopoietic stem cells (HSCs) are tightly controlled to maintain a balance between blood cell production and self-renewal. While inflammation-related signaling is a critical regulator of HSC activity, the underlying mechanisms and the precise functions of specific factors under steady-state and stress conditions remain incompletely understood. We...
Borate, Uma Yang, Fei Press, Richard Ruppert, Amy Jones, Dan Caruthers, Sean Zhao, Weiqiang Vergilio, Jo-Anne Pavlick, Dean Juckett, Luke
...
Next-generation sequencing (NGS) to identify pathogenic mutations is an integral part of acute myeloid leukemia (AML) therapeutic decision-making. The concordance in identifying pathogenic mutations among different NGS platforms at different diagnostic laboratories has been studied in solid tumors but not in myeloid malignancies to date. To determi...
Gore, Steven Kroft, Steven Harrington, Alexandra Saber, Wael Starczynowski, Daniel Rollison, Dana Zhang, Ling Moscinski, Lynn Wilson, Steffanie Thompson, Jason
...
Myelodysplastic neoplasms (MDS) are a collection of hematopoietic disorders with widely variable prognoses and treatment options. Accurate pathologic diagnoses present challenges because of interobserver variability in interpreting morphology and quantifying dysplasia. We compared local clinical site diagnoses with central, adjudicated review from ...
Meyers, Sarah Demeyer, Sofie Cools, Jan
Published in
Journal of hematology & oncology
The CRISPR genome editing technology has revolutionized the way gene function is studied. Genome editing can be achieved in single genes or for thousands of genes simultaneously in sensitive genetic screens. While conventional genetic screens are limited to bulk measurements of cell behavior, recent developments in single-cell technologies make it ...
Meyers, Sarah; 132329; Demeyer, Sofie; 97449; Cools, Jan; 16417;
The CRISPR genome editing technology has revolutionized the way gene function is studied. Genome editing can be achieved in single genes or for thousands of genes simultaneously in sensitive genetic screens. While conventional genetic screens are limited to bulk measurements of cell behavior, recent developments in single-cell technologies make it ...
Hong, Yun Battle, Stephanie Shi, Wen Puiu, Daniela Pillalamarri, Vamsee Xie, Jiaqi Pankratz, Nathan Lake, Nicole Lek, Monkol Rich, Stephen
...
Mitochondria carry their own circular genome and disruption of the mitochondrial genome is associated with various aging-related diseases. Unlike the nuclear genome, mitochondrial DNA (mtDNA) can be present at 1000 s to 10,000 s copies in somatic cells and variants may exist in a state of heteroplasmy, where only a fraction of the DNA molecules har...
Moreno, Carol Solman, Isabelle Tam, Constantine Grigg, Andrew Scarfò, Lydia Srinivasan, Srimathi Mali, Raghuveer Zhou, Cathy Dean, James Szafer-Glusman, Edith
...
We evaluated immune cell subsets in patients with chronic lymphocytic leukemia (CLL) who received first-line therapy with 3 cycles of ibrutinib then 13 cycles of ibrutinib plus venetoclax in the minimal residual disease (MRD) cohort of the CAPTIVATE study (NCT02910583). Patients with Confirmed undetectable MRD (uMRD) were randomly assigned to place...
Bilgihan, Muhammed Talha Eryigit, Ayse Nur Ciftciler, Rafiye
Published in
Clinical lymphoma, myeloma & leukemia
The emergence of immune checkpoint inhibitors (ICIs) has led to a dramatic paradigm shift within the landscape of cancer treatment, igniting significant interest in their potential application in treating hematologic malignancies. This comprehensive review critically has examined the existing body of literature to shed light on the evolving underst...
